PAXMAN – a pioneer in scalp cooling – recently outlined its ambitions to ‘chase zero hair loss during chemotherapy’ at the 2015 European Cancer Congress, held in Vienna.
Paxman continues to heavily invest in new R&D, funding multi-disciplinary research groups and conducting clinical trials to help improve the efficiency of scalp cooling and ultimately raise the success rate of ‘zero hair loss’ from 50/50 to 80/20 by the year 2020
The company has founded an international multi-disciplinary special interest group (SIG) to look into chemotherapy-induced alopecia (CIA) and scalp cooling. Research will include reduced post infusion cooling times, further in-vitro modelling to better understand the mechanisms of scalp cooling, understanding the role in temperature with different chemotherapy regimens and measuring patient comfort.
Paxman is also proposing maintaining a registry of all scalp cooling patients in the UK, in order to undertake epidemiological studies of large groups of scalp cooling patients to track their long-term health. The company is also undertaking a series of clinical trials and is developing a third-generation version of the cooling cap to ensure it fits more efficiently.
Richard Paxman, managing director of Paxman, said: “We know scalp cooling works so our aim is to raise the success rate for all patients undergoing chemotherapy so no one ever has to lose their hair as a side effect of cancer.”
